CUE Stock Forecast: Cue Biopharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.15
−7.78% on the day

The median 12-month analyst price target for Cue Biopharma, Inc. is $66. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$37.6M
Ticker Nerd rank
20/ 100
Median analyst target
$66
Analysts covering
3
Revenue$7.9M+166.7% y/y
Operating income−$87.7M
Net income−$153.1M
Free cash flow−$29.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−74.3%
1M
−75.6%
YTD
−54.6%
1Y
−74.4%
From 52W high
−89.0%
From 52W low
+46.6%
$3
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Cue Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
20/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Momentum
42
Revisions
33
Growth
30
Quality
27
Value
15
Issuance
10
Volatility
5

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (5): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120Jan 26Apr 26Jul 26Oct 26CUEHigh $115Median $66Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$25
Low
$66
Median
$115
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Nov 2026B. Riley SecuritiesReiteratesBuy$83 → $25
18 Sept 2026B. Riley SecuritiesInitiatesBuy$83
25 Aug 2025LUCID CAPITAL MARKETSInitiatesBuy$4.00
2 Apr 2025Citizens Capital MarketsReiteratesMarket Outperform—
20 Aug 2024StifelMaintainsBuy—
26 July 2024JMP SecuritiesMaintainsMarket Outperform—
26 July 2024Piper SandlerMaintainsOverweight—
9 Apr 2024OppenheimerMaintainsOutperform—
9 Apr 2024StifelMaintainsBuy—
3 Apr 2024Piper SandlerReiteratesOverweight—
13 Mar 2024JefferiesInitiatesBuy—
6 Nov 2023Piper SandlerMaintainsOverweight—
26 June 2023OppenheimerAssumesOutperform$10
15 June 2023StifelReiteratesBuy—
15 May 2023JMP SecuritiesReiteratesOutperform—
22 Mar 2023OppenheimerReiteratesOutperform—
22 Mar 2023StifelMaintainsBuy—
21 Nov 2022Piper SandlerInitiatesOverweight—
24 Aug 2022OppenheimerMaintainsOutperform—
21 Mar 2022OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CUE.

Market Radar

This page is one stock. Monday covers all of them.

CUE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Cue Biopharma, Inc. returned −74.4% against +6.9% for the S&P 500, dividends included.

CUE vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250Jan 26Apr 26Jul 26Oct 26CUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.1×

Cheaper than 64% of US stocks

Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−800.4%

Higher than 2% of US stocks

Return on assets
−174.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cue Biopharma, Inc. has a market value of $37.6M.

  • Revenue in the twelve months to 30 June 2026: $37.7M. The latest quarter grew 166.7% year on year.

  • Net income over the same four quarters: −$164.1M, a −435.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$27.02.

  • Free cash flow in the twelve months to 30 June 2026: −$50.2M.

  • Shares outstanding: 5.2M.

  • Cue Biopharma, Inc. employs 29 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CUE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CUECue Biopharma, Inc.$37.6M20
TILInstil Bio, Inc.$35.5M48
GRCEGrace Therapeutics, Inc.$36.0M44
VERUVeru, Inc.$33.1M51
ATNMActinium Pharmaceuticals, Inc.$32.9M87
PLRXPliant Therapeutics, Inc.$36.8M68
GRDXGridAI Technologies Corp.$32.4M16

Take a look at CUE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Cue Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CUE

What is the CUE stock price forecast for 2026-2027?

The median 12-month analyst price target for Cue Biopharma, Inc. is $66, with estimates ranging from $25 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CUE stock a buy right now?

Of the 3 analysts covering Cue Biopharma, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cue Biopharma, Inc. 20 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CUE?

As at 21 Nov 2026, Cue Biopharma, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will CUE stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $66, and Ticker Nerd's factor model ranks Cue Biopharma, Inc. 20 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CUE stock forecast for 2030?

No analyst covering Cue Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $115 over the next 12 months.

How has CUE stock performed over the past year?

Cue Biopharma, Inc. returned -74.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cue Biopharma, Inc. do?

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression.

Company

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression. The company’s lead asset, CUE-221, is an anti-IgE antibody being advanced for allergic diseases, while CUE-401 is a bifunctional IL-2 and TGF-β program designed to support Treg-mediated tolerance in autoimmune conditions. Cue Biopharma’s Immuno-STAT platform underpins its product development approach, enabling targeted immune modulation across immunological disorders. Based in Boston, Massachusetts, Cue Biopharma participates in the biotechnology sector through a pipeline aimed at addressing unmet medical needs in allergy, inflammation, and autoimmunity.

CEO Dr. Shao-Lee Lin M.D., Ph.D. · 29 employees · United States · https://www.cuebiopharma.com